ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial
Highlight
– In ENLIGHTEN, ANK3-positive patients with treatment‑resistant depression (TRD) randomized to liafensine (1 or 2 mg daily) had a statistically and clinically significant greater reduction in MADRS score at day 42 than placebo (mean difference −4.4 points, 95% CI −7.6 to −1.3; P = .006).
– This is the first prospective, randomized, biomarker‑guided clinical trial in psychiatry reporting successful enrichment of responders using a genetic marker (ANK3).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.